News | Atrial Fibrillation | May 18, 2023

Vektor Medical Releases Compelling Results for vMap Utility

vMap’s use with ‘Unmappable’ Ventricular Tachycardia Ablation and Accurate Proof-of-Concept Mapping Using Outpatient 12-lead ECG Data to be Presented at the Heart Rhythm Society’s Annual Conference in New Orleans

The first of Vektor Medical's new studies, being presented at HRS 2023, showcases vMap’s utility in unstable ventricular tachycardia (VT) ablation. (Graphic: Business Wire)

The first of Vektor Medical's new studies, being presented at HRS 2023, showcases vMap’s utility in unstable ventricular tachycardia (VT) ablation. (Graphic: Business Wire)

May 18, 2023 — Vektor Medical, pioneers of technology to accurately map arrhythmias using only 12-lead ECG data, unveiled two studies further demonstrating clinical utility. The first study showcases vMap’s utility in unstable ventricular tachycardia (VT) ablation, sometimes called ‘unmappable VT’. The second study, a proof-of-concept effort, demonstrated a brand-new opportunity to map Atrial Tachycardia using 12-lead ECG data obtained in the outpatient setting. Results will be presented at the Heart Rhythm Society’s Annual Conference 2023 in New Orleans.

vMap, an FDA-cleared electrophysiology device, utilizes advanced machine learning techniques and proprietary computational models to extract functional insights for accurate and efficient arrhythmia source location from a standard 12-lead ECG, without requiring invasive mapping techniques.

The first study, ‘Prospective Real-Time Use of Forward-Solution ECG Mapping to Facilitate Focused Activation Mapping of Unstable Ventricular Tachycardia (VT): Accuracy and Outcomes,’ demonstrated the accuracy and utility of vMap for mapping hemodynamically unstable VT during catheter ablation procedures. Out of 16 consecutive patients who underwent VT ablation, seven of the eight patients undergoing prospective ECG mapping had hemodynamically unstable VT. All seven VT patients had successful activation mapping guided by vMap. The results demonstrated a path forward for mapping these ‘unmappable’ VT while indicating an improvement in patient outcomes and further validating vMap’s accuracy for arrhythmia source identification, including:

  • 98% reduction in total VT episodes during mean 4.2 month follow-up
  • Mean accuracy of ECG mapping was 1.2±0.8cm when compared to invasive activation for all 16 patients

The second proof-of-concept study demonstrated vMap’s utility with outpatient 12-lead ECGs to accurately identify an Atrial Tachycardia (AT) arrhythmia source location. In the study, “Proof-of-Concept Forward-Solution Mapping of a Focal Atrial Tachycardia Origin Using the Outpatient 12-Lead Electrocardiogram,” the outpatient ECG was loaded into vMap and target AT locations were identified with the computational modeling software. The arrhythmia source location was then confirmed using invasive mapping techniques. Additional validation is ongoing in larger populations, but early results demonstrated:

  • Agreement between vMap’s non-invasively identified location at the anterior base of the left atrial appendage as the highest probability focal AT source, with the location identified by invasive electron anatomical mapping techniques.
  • The arrhythmia source accuracy of the vMap as compared to invasive mapping was 8.8mm as defined by center-to-center spatial distance between the sites of early activation.

“Arrhythmia source mapping is a crucial component of targeted catheter ablation procedures for complex procedures and helps us to ensure effective and durable therapy,” commented Dr. Gordon Ho, Electrophysiologist at UC San Diego Health and lead author of the VT study. “vMap provides actionable information about where the sources most likely are to help drive procedural efficiency in challenging cases such as unstable VT and complex AF. I’ve been impressed with how easy the system is to incorporate into our workflow and the value it adds to more quickly identify target lesion sites.”

The results add to the growing body of evidence that demonstrates vMap’s utility for the successful treatment of a wide range of arrhythmias.

For more information:

Find more HRS conference coverage here


Related Content

News | HRS

September 21, 2023 — Vektor Medical, developers of the only FDA-cleared technology to accurately map arrhythmias using ...

Home September 21, 2023
Feature | HRS | By Melinda Taschetta-Millane

The Heart Rhythm Society (HRS) announced the full lineup of speakers and sessions, including late-breaking clinical ...

Home May 17, 2023
News | HRS

May 2, 2023 — The Heart Rhythm Society (HRS) is making final preparations for its Annual Heart Rhythm Meeting, HRS2023 ...

Home May 02, 2023
Feature | HRS | By Lars Thording, PhD

Hospitals in the U.S. are suffering under a debilitating post-pandemic financial and operational trauma. Ascension ...

Home August 23, 2022
News | HRS

August 4, 2022 — The Heart Rhythm Society (HRS) is a professional society representing a diverse population of ...

Home August 04, 2022
News | HRS

May 17, 2022 — Heart Rhythm 2022 has come to a close, and the Heart Rhythm Society has released some stats regarding ...

Home May 17, 2022
Videos | HRS

Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of ...

Home May 22, 2020
Feature | HRS

May 20, 2020 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of them ...

Home May 20, 2020
Feature | HRS | Dave Fornell, Editor

May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm ...

Home May 15, 2019
Feature | HRS | Dave Fornell

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) ...

Home May 18, 2018
Subscribe Now